No Data
No Data
Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $20
Sonnet BioTherapeutics Analyst Ratings
Sonnet BioTherapeutic | 10-K: FY2024 Annual Report
Express News | Sonnet BioTherapeutics FY 2024 GAAP EPS $(11.35)
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
Express News | Sonnet Biotherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
No Data